Drug Profile
BSL02 150929Y
Alternative Names: BSL02-150929YLatest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Kao Corporation
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Erythema
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for phase-I development in Erythema(Prevention) in Japan (Topical)
- 29 Sep 2016 Kao Corporation completes a phase-I clinical trial in Erythema (Prevention) in Japan (Topical) (UMIN000019152)
- 26 Oct 2015 Phase-I clinical trials in Erythema (Prevention) in Japan (Topical) (UMIN000019152)